Rentiapril racemate

CAS No. 72679-47-1

Rentiapril racemate( —— )

Catalog No. M33478 CAS No. 72679-47-1

Rentiapril racemate (SA-446 racemate) is the racemic form of Rentiapril, exhibiting anti-inflammatory properties and potential applications in glaucoma research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 182 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Rentiapril racemate
  • Note
    Research use only, not for human use.
  • Brief Description
    Rentiapril racemate (SA-446 racemate) is the racemic form of Rentiapril, exhibiting anti-inflammatory properties and potential applications in glaucoma research.
  • Description
    Rentiapril racemate (SA-446 racemate) is the racemate of Rentiapril. Rentiapril is an angiotensin converting enzyme (ACE) inhibitor.
  • In Vitro
    ——
  • In Vivo
    A three-months toxicity study of an angiotensin converting enzyme (ACE) inhibitor, Rentiapril (CAS 80830-42-8), is performed in Sprague-Dawley rats by oral administration. The dose levels of 0, 30, 125, 500 and 1000 mg/kg are tested in both sexes, in which each experimental group comprised 10 rats. Another ACE inhibitor, captopril, is used as a reference compound. Rentiapril at the highest dose of 1000 mg/kg causes low food consumption and death of some animals with signs of bloody feces and anemia. In males and females receiving 500 and 1000 mg/kg, there are low body weight gain, increases in water intake, urine volume and serum BUN level, and decreases in levels of various erythrocytic parameters. Kidney weight is increased dose-dependently in both sexes. Histopathologically, renal changes in the 500 and 1000 mg/kg groups consist of proximal tubular degeneration, juxtaglomerular cell hyperplasia and interstitial cell infiltration. Similar, but mild, changes in proximal tubules are present in the female 125 mg/kg group. Dead animals from the highest dose groups further show gastrointestinal hemorrhagic erosion and/or ulcer, decrease bone marrow erythropoiesis and hepatocytic vacuolar degeneration. There is no pathological alteration in rats from other Rentiapril-treated groups, as well as in controls. These results indicate that the no-effect dose of Rentiapril in rats by three months oral administration is 30 mg/kg in female and 125 mg/kg in male.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    ACE
  • Recptor
    Angiotensin-converting Enzyme (ACE)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    72679-47-1
  • Formula Weight
    313.39
  • Molecular Formula
    C13H15NO4S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (319.09 mM; Ultrasonic )
  • SMILES
    OC(=O)C1CSC(N1C(=O)CCS)c1ccccc1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Takase K, et al. Toxicity study of the angiotensin converting enzyme inhibitor rentiapril in rats. Arzneimittelforschung. 1995 Jan;45(1):15-8.?
molnova catalog
related products
  • H-Ile-Pro-Pro-OH

    H-Ile-Pro-Pro-OH, a milk-derived peptide, inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 μM.

  • Rentiapril racemate

    Rentiapril racemate (SA-446 racemate) is the racemic form of Rentiapril, exhibiting anti-inflammatory properties and potential applications in glaucoma research.

  • Gemopatrilat

    A potent, orally available, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 12 and 63 nM, respectively.